Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Recruiting now

Conditions studied: Leukemia, Myeloid, Acute

In brief

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

Key facts

Study ID

NCT06580106

Run by

Wake Forest University Health Sciences

People needed

50

Starts

2025-04-09

Expected to finish

2030-01-01

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent and HIPAA authorization for release of personal health information.
• Age ≥ 18 years of age at the time of consent
• Confirmed diagnosis of AML
• Planned initial treatment with azacitidine and venetoclax
• Ability to read and understand the English and/or Spanish language
• As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study

You may not qualify if…

• None

Where it is running

• Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
• Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.